A phase II study employing combination regimens containing KRN8602 in drug-resistant acute myeloid leukemia and acute lymphoblastic leukemia. KRN8602 Leukemia Study Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples